Dr Kim Nguyen Chi speaks to ecancer about the CCTG PR.21 phase II randomised trial that directly compares 177Lu-PSMA-617 (LU-P), a radioligand therapy targeting PSMA, with docetaxel (DOC) chemotherapy in chemotherapy-naïve patients.

The study found that while radiographic progression-free survival was similar, 177Lu-PSMA-617 demonstrated superior PSA response and lower toxicity, suggesting a meaningful role in preserving quality of life.

However Dr Chi highlights that overall survival favoured docetaxel, highlighting a potential trade-off between disease control and long-term outcomes.

He concludes by saying that these data support the need for personalised treatment approaches in mCRPC based on patient goals, disease biology, and tolerance.